Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + SBRT in ES-SCLC
NCT04951115Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Jul 2021
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by Weill Cornell Medicine. Primary endpoints: Number of Toxicities Grade 3 or Above Related to Therapy up to 29 months and Efficacy of Multi-site, Non-ablative Radiation to Standard Systemic Therapy up to 12 months. Started Jul 2021; status: terminated.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04951115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951115.